HUE052926T2 - Arginin metiltranszferáz inhibitorok és ezek alkalmazása - Google Patents

Arginin metiltranszferáz inhibitorok és ezek alkalmazása

Info

Publication number
HUE052926T2
HUE052926T2 HUE14717371A HUE14717371A HUE052926T2 HU E052926 T2 HUE052926 T2 HU E052926T2 HU E14717371 A HUE14717371 A HU E14717371A HU E14717371 A HUE14717371 A HU E14717371A HU E052926 T2 HUE052926 T2 HU E052926T2
Authority
HU
Hungary
Prior art keywords
methyltransferase inhibitors
arginine methyltransferase
arginine
inhibitors
methyltransferase
Prior art date
Application number
HUE14717371A
Other languages
English (en)
Hungarian (hu)
Inventor
Richard Chesworth
Lorna Mitchell
Gideon Shapiro
Keren Kalai Swinger
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc filed Critical Epizyme Inc
Publication of HUE052926T2 publication Critical patent/HUE052926T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE14717371A 2013-03-14 2014-03-14 Arginin metiltranszferáz inhibitorok és ezek alkalmazása HUE052926T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361781051P 2013-03-14 2013-03-14
US201361876034P 2013-09-10 2013-09-10

Publications (1)

Publication Number Publication Date
HUE052926T2 true HUE052926T2 (hu) 2021-05-28

Family

ID=50483598

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14717371A HUE052926T2 (hu) 2013-03-14 2014-03-14 Arginin metiltranszferáz inhibitorok és ezek alkalmazása

Country Status (24)

Country Link
US (5) US9598374B2 (enExample)
EP (1) EP2970132B1 (enExample)
JP (1) JP6581076B2 (enExample)
KR (2) KR102028793B1 (enExample)
CN (2) CN105339351B (enExample)
AU (2) AU2014236146B2 (enExample)
BR (1) BR112015022785A2 (enExample)
CA (1) CA2903394C (enExample)
CY (1) CY1123637T1 (enExample)
DK (1) DK2970132T3 (enExample)
EA (1) EA030481B1 (enExample)
ES (1) ES2837034T3 (enExample)
HR (1) HRP20202008T1 (enExample)
HU (1) HUE052926T2 (enExample)
IL (2) IL241368B (enExample)
LT (1) LT2970132T (enExample)
MX (1) MX382991B (enExample)
PL (1) PL2970132T3 (enExample)
PT (1) PT2970132T (enExample)
RS (1) RS61231B1 (enExample)
SG (1) SG11201506972PA (enExample)
SI (1) SI2970132T1 (enExample)
WO (1) WO2014153226A1 (enExample)
ZA (1) ZA201507441B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY199894A (en) 2012-12-21 2023-11-27 Epizyme Inc Prmt5 inhibitors and uses thereof
CA2894157A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
WO2014100716A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
JP2016505000A (ja) 2012-12-21 2016-02-18 エピザイム，インコーポレイティド Ｐｒｍｔ５阻害剤およびその使用
JP2016505002A (ja) 2012-12-21 2016-02-18 エピザイム，インコーポレイティド ジヒドロイソキノリンまたはテトラヒドロイソキノリンを含有するｐｒｍｔ５阻害剤およびその使用
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970134B1 (en) 2013-03-14 2018-02-28 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
SG11201506972PA (en) * 2013-03-14 2015-10-29 Epizyme Inc Arginine methyltransferase inhibitors and uses thereof
WO2014153208A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970136A1 (en) 2013-03-14 2016-01-20 Epizyme, Inc. Arginine methyl transferase inhibtors and uses thereof
US9394258B2 (en) 2013-03-14 2016-07-19 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970133B1 (en) 2013-03-14 2018-10-24 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
AU2014260433A1 (en) 2013-03-14 2015-09-10 Epizyme, Inc. Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof
WO2014144659A1 (en) 2013-03-14 2014-09-18 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US20160031839A1 (en) 2013-03-14 2016-02-04 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970266B1 (en) 2013-03-15 2018-01-31 Epizyme, Inc. 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof
KR20160003647A (ko) 2013-03-15 2016-01-11 에피자임, 인코포레이티드 Carm1 억제제 및 이의 용도
US9346802B2 (en) 2013-03-15 2016-05-24 Epizyme, Inc. CARM1 inhibitors and uses thereof
CA2953572A1 (en) 2014-08-04 2016-02-11 Epizyme, Inc. Prmt5 inhibitors and uses thereof
WO2016044576A1 (en) * 2014-09-17 2016-03-24 Epizyme, Inc. Salts, co-crystals, amorphous forms, and crystalline forms of an arginine methyltransferase inhibitor
AU2017367300A1 (en) 2016-12-01 2019-06-13 Glaxosmithkline Intellectual Property Development Limited Combination therapy
CN110225983A (zh) * 2016-12-01 2019-09-10 葛兰素史密斯克莱知识产权发展有限公司 治疗癌症的方法
US20190343803A1 (en) * 2016-12-01 2019-11-14 Glaxosmithkline Intellectual Property Development Limited Combination therapy
CA3092579A1 (en) 2018-03-01 2019-09-06 Board Of Regents, The University Of Texas System Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases
BR112020023459A2 (pt) * 2018-05-31 2021-02-23 Glaxosmithkline Intellectual Property Development Limited terapia combinada com proteínas de ligação a icos e inibidores de arginina metiltransferase
WO2020182018A1 (zh) * 2019-03-12 2020-09-17 四川科伦博泰生物医药股份有限公司 氮杂环化合物、其制备方法及用途
IL318073A (en) * 2019-03-25 2025-02-01 California Inst Of Techn PRMT5 inhibitors and their uses
WO2021023609A1 (en) * 2019-08-02 2021-02-11 Glaxosmithkline Intellectual Property Development Limited Combination of a type i protein arginine methyltransferase (type i prmt) inhibitor and a methionine adenosyltransferase ii alpha (mat2a) inhibitor
CN110950841A (zh) * 2019-11-22 2020-04-03 济南大学 一类新型三唑类化合物的合成及应用
KR102219251B1 (ko) 2020-03-03 2021-02-22 김명수 전문가 추천 플랫폼을 제공하는 서버 및 그 운용방법
CN111481532B (zh) * 2020-06-28 2020-09-22 南京中澳转化医学研究院有限公司 化合物28d在制备提高γ-珠蛋白表达量的药物中的应用

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH085859B2 (ja) 1986-07-01 1996-01-24 日本バイエルアグロケム株式会社 新規アルキレンジアミン類
US5204482A (en) 1988-07-28 1993-04-20 Hoffman-Laroche Inc. Compounds for treating and preventing cognitive diseases and depression and methods of making same
EP0352581A3 (de) 1988-07-28 1990-07-04 F. Hoffmann-La Roche Ag Aethylendiaminmonoamid-Derivate
JPH11501289A (ja) 1994-12-02 1999-02-02 藤沢薬品工業株式会社 Ｎｏ介在疾患の予防および／または治療のためのペプチド化合物
SE9902765D0 (sv) 1999-07-21 1999-07-21 Astra Pharma Prod Novel compounds
CN1331326A (zh) * 2000-06-30 2002-01-16 上海博德基因开发有限公司 一种新的多肽——人精氨酸甲基转移酶(hrmt)32.12和编码这种多肽的多核苷酸
US20020090627A1 (en) 2000-10-05 2002-07-11 Rachel Meyers 27419, a novel human arginine-N-methyl transferase and uses thereof
DE10149370A1 (de) 2001-10-06 2003-04-10 Merck Patent Gmbh Pyrazolderivate
KR20040090978A (ko) 2002-03-13 2004-10-27 얀센 파마슈티카 엔.브이. 히스톤 디아세틸라제의 신규한 저해제로서의 설포닐-유도체
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US7759336B2 (en) 2002-12-10 2010-07-20 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compounds and medicinal use thereof
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
DE10315572A1 (de) 2003-04-05 2004-10-14 Merck Patent Gmbh Substituierte Pyrazole
GB0309637D0 (en) 2003-04-28 2003-06-04 Cancer Rec Tech Ltd Pyrazole compounds
WO2004098634A2 (en) 2003-04-30 2004-11-18 Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health Protein arginine n-methyltransferase 2 (prmt-2)
US20050032794A1 (en) 2003-08-05 2005-02-10 Padia Janak K. Diamine derivatives of quinone and uses thereof
DE102004008807A1 (de) 2004-02-20 2005-09-08 Bayer Cropscience Ag Pyrazolopyrimidine
SI1725537T1 (sl) 2004-03-15 2011-11-30 Janssen Pharmaceutica Nv Nove spojine kot modulatorji opioidnih receptorjev
DK1784396T3 (da) 2004-08-26 2011-02-14 Pfizer Pyrazol-substituerede aminoheteroaryl-forbindelser som proteinkinase-inhibitorer
ES2335411T3 (es) 2004-08-31 2010-03-26 University Of North Carolina At Chapel Hill Dot1 histona metiltransferasas como diana para identificar agentes terapeuticos para leucemia.
WO2006033995A2 (en) 2004-09-16 2006-03-30 Valeant Research And Development Thiazolidin-4-ones having anti-hepatitis b activity
WO2006040136A1 (en) 2004-10-13 2006-04-20 Bayer Healthcare Ag Substituted 4-benzyloxy-phenylmethylamide derivatives as cold menthol receptor-1 (cmr-1) antagonists for the treatment of urological disorder
US9550990B2 (en) 2004-12-10 2017-01-24 Ionis Pharmaceuticals, Inc. Regulation of epigenetic control of gene expression
US20070060589A1 (en) 2004-12-21 2007-03-15 Purandare Ashok V Inhibitors of protein arginine methyl transferases
WO2006077428A1 (en) 2005-01-21 2006-07-27 Astex Therapeutics Limited Pharmaceutical compounds
WO2006113458A1 (en) * 2005-04-15 2006-10-26 Bristol-Myers Squibb Company Heterocyclic inhibitors of protein arginine methyl transferases
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
CA2617980A1 (en) 2005-08-19 2007-03-01 Aventis Pharmaceuticals Inc. Combination of a hypnotic agent and substituted bis aryl and heteroaryl compound and therapeutic application thereof
JP5015016B2 (ja) 2006-02-07 2012-08-29 大正製薬株式会社 １０ａ−アザライド化合物
WO2007149782A2 (en) 2006-06-23 2007-12-27 University Of Medicine And Dentistry Of New Jersey Selective inhibitors for transferases
EP2035436B1 (en) 2006-06-26 2011-05-25 UCB Pharma S.A. Fused thiazole derivatives as kinase inhibitors
AU2007273057A1 (en) * 2006-07-12 2008-01-17 Merck Sharp & Dohme Corp. Substituted pyrazoles as ghrelin receptor antagonists
WO2008032191A2 (en) 2006-09-13 2008-03-20 Astrazeneca Ab Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
PL2076260T3 (pl) 2006-09-15 2011-08-31 Celgene Corp Związki N-metyloaminometylo-izoindolu, kompozycje zawierające te związki, oraz metody ich stosowania
US8338437B2 (en) 2007-02-28 2012-12-25 Methylgene Inc. Amines as small molecule inhibitors
WO2008128050A2 (en) 2007-04-11 2008-10-23 Osi Pharmaceuticals, Inc. Methods for identification of modulators of carm1 methyl transferase activity
WO2008137834A2 (en) 2007-05-04 2008-11-13 Osi Pharmaceuticals, Inc. Crystal structure of smyd3 protein
WO2009006577A2 (en) 2007-07-03 2009-01-08 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
US8133904B2 (en) 2007-09-07 2012-03-13 Jenrin Discovery, Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
EP2226315A4 (en) 2007-12-28 2012-01-25 Carna Biosciences Inc 2-aminoquinazoline DERIVATIVE
JP2009179616A (ja) 2008-01-31 2009-08-13 Kowa Co ３−ナフチルピラゾール化合物
JP5539235B2 (ja) 2008-02-29 2014-07-02 エボテック・アーゲー アミド化合物、組成物およびそれらの使用
WO2009126537A1 (en) 2008-04-07 2009-10-15 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac and an hmt inhibitor
US8512944B2 (en) 2008-08-27 2013-08-20 Oncotherapy Science, Inc. PRMT1 for target genes of cancer therapy and diagnosis
ES2546404T3 (es) 2008-09-24 2015-09-23 Basf Se Compuestos de pirazol para el control de plagas invertebradas
US8323918B2 (en) 2008-12-12 2012-12-04 University Of South Carolina Chloroacetamidine based inhibitors and activity based probes for the protein arginine methytransferases
WO2010094009A2 (en) 2009-02-13 2010-08-19 Children's Hospital Medical Center Methods and compositions for the treatment of ras associated disorders
US20130345268A1 (en) 2009-02-13 2013-12-26 The Trustees Of Dartmouth College Methods and Compositions for the Treatment of RAS Associated Disorders
EP2221053A1 (de) 2009-02-20 2010-08-25 Albert-Ludwigs-Universität Freiburg Pharmazeutische Zusammensetzung enthaltend Hemmstoffe der Proteinmethyltransferase I und deren Verwendung zur Behandlung von Tumorerkrankungen
BRPI1011505A2 (pt) * 2009-03-11 2016-03-22 Auckland Uniservices Ltd formas de pró-drogas de inibidores de quinase e sua aplicação em terapia
IN2012DN00352A (enExample) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
US20110021362A1 (en) 2009-07-20 2011-01-27 Constellation Pharmaceuticals Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
US9044432B2 (en) 2009-12-22 2015-06-02 Ohio State Innovation Foundation Compositions and methods for cancer detection and treatment
WO2011082098A1 (en) 2009-12-30 2011-07-07 The Rockefeller University Lysine and arginine methyltransferase inhibitors for treating cancer
WO2011096210A1 (en) 2010-02-03 2011-08-11 Oncotherapy Science, Inc. Prmt1 and prmt6 for target genes of cancer therapy and diagnosis
EP2531598A4 (en) 2010-02-03 2013-05-22 Oncotherapy Science Inc WHSC1 AND WHSC1L1 FOR TARGET GENES TO CANCER THERAPY AND DIAGNOSIS
US20110251216A1 (en) 2010-02-19 2011-10-13 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
ES2528269T3 (es) 2010-05-07 2015-02-06 Glaxosmithkline Llc Azaindazoles
HRP20170736T1 (hr) 2010-05-07 2017-07-28 Glaxosmithkline Llc Indoli
JP6389036B2 (ja) 2010-09-10 2018-09-12 エピザイム インコーポレイテッド ヒトｅｚｈ２の阻害剤、およびその使用方法
WO2012060760A1 (en) 2010-11-05 2012-05-10 Fujirebio Diagnostics Ab Molecular marker for cancer
WO2012068589A2 (en) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
EP2646020B1 (en) 2010-12-01 2016-09-21 Glaxosmithkline LLC Indoles
CA2819625A1 (en) 2010-12-03 2012-06-07 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
US8580762B2 (en) 2010-12-03 2013-11-12 Epizyme, Inc. Substituted purine and 7-deazapurine compounds
CA2819620A1 (en) 2010-12-03 2012-06-21 Epizyme, Inc. Modulators of histone methyltransferase, and methods of use thereof
AU2011336264A1 (en) 2010-12-03 2013-06-20 Epizyme, Inc. Carbocycle-substituted purine and 7-deazapurine compounds
EP3323820B1 (en) 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
WO2013174947A1 (en) 2012-05-23 2013-11-28 Stemergie Biotechnology Sa Inhibitors of the activity of complex (iii) of the mitochondrial electron transport chain and use thereof
MX356341B (es) 2012-08-30 2018-05-23 Univ Tokyo Agente de control de endoparasitos.
ES2661375T3 (es) 2012-08-30 2018-03-28 The University Of Tokyo Agente endoparasiticida y método para usarlo
JP2016505002A (ja) 2012-12-21 2016-02-18 エピザイム，インコーポレイティド ジヒドロイソキノリンまたはテトラヒドロイソキノリンを含有するｐｒｍｔ５阻害剤およびその使用
CA2894157A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
WO2014100716A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
CA2894230A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Methods of inhibiting prmt5
MY199894A (en) 2012-12-21 2023-11-27 Epizyme Inc Prmt5 inhibitors and uses thereof
JP2016505000A (ja) 2012-12-21 2016-02-18 エピザイム，インコーポレイティド Ｐｒｍｔ５阻害剤およびその使用
EP2970136A1 (en) 2013-03-14 2016-01-20 Epizyme, Inc. Arginine methyl transferase inhibtors and uses thereof
EP2970134B1 (en) 2013-03-14 2018-02-28 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
WO2014144659A1 (en) 2013-03-14 2014-09-18 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US20160031839A1 (en) 2013-03-14 2016-02-04 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970133B1 (en) 2013-03-14 2018-10-24 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9394258B2 (en) 2013-03-14 2016-07-19 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
AU2014260433A1 (en) 2013-03-14 2015-09-10 Epizyme, Inc. Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof
WO2014153208A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
SG11201506972PA (en) * 2013-03-14 2015-10-29 Epizyme Inc Arginine methyltransferase inhibitors and uses thereof
KR20160003647A (ko) 2013-03-15 2016-01-11 에피자임, 인코포레이티드 Carm1 억제제 및 이의 용도
US9346802B2 (en) 2013-03-15 2016-05-24 Epizyme, Inc. CARM1 inhibitors and uses thereof
EP2970266B1 (en) 2013-03-15 2018-01-31 Epizyme, Inc. 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof
EP3160466A4 (en) 2014-06-25 2017-12-27 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US20170198006A1 (en) 2014-06-25 2017-07-13 Epizyme, Inc. Prmt5 inhibitors and uses thereof
CA2953572A1 (en) 2014-08-04 2016-02-11 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US20170280720A1 (en) 2014-09-17 2017-10-05 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2016044650A1 (en) 2014-09-17 2016-03-24 Epizyme, Inc. Carm1 inhibitors and uses thereof
WO2016044569A1 (en) 2014-09-17 2016-03-24 Epizyme, Inc. Salts, co-crystals, amorphous forms, and crystalline forms of a co-activator-associated arginine methyltransferase 1 (carm1) inhibitor
US20170291905A1 (en) 2014-09-17 2017-10-12 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
JP2017530959A (ja) 2014-09-17 2017-10-19 エピザイム，インコーポレイティド Ｃａｒｍ１阻害剤およびその使用
WO2016044641A2 (en) 2014-09-17 2016-03-24 Epizyme, Inc. Carm1 inhibitors and uses thereof
US20170283400A1 (en) 2014-09-17 2017-10-05 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2016044576A1 (en) 2014-09-17 2016-03-24 Epizyme, Inc. Salts, co-crystals, amorphous forms, and crystalline forms of an arginine methyltransferase inhibitor
WO2017136699A1 (en) 2016-02-05 2017-08-10 Epizyme, Inc Arginine methyltransferase inhibitors and uses thereof
US20190083482A1 (en) 2017-09-18 2019-03-21 Epizyme, Inc. Prmt5 inhibitors and uses thereof

Also Published As

Publication number Publication date
US10081603B2 (en) 2018-09-25
US11512053B2 (en) 2022-11-29
KR102028793B1 (ko) 2019-10-07
KR102158756B1 (ko) 2020-09-23
US9598374B2 (en) 2017-03-21
MX2015012850A (es) 2016-06-24
EA201591531A1 (ru) 2016-02-29
PT2970132T (pt) 2020-12-30
BR112015022785A2 (pt) 2017-07-18
US10800743B2 (en) 2020-10-13
LT2970132T (lt) 2021-01-11
HK1219736A1 (zh) 2017-04-13
JP2016516067A (ja) 2016-06-02
US20170267642A1 (en) 2017-09-21
JP6581076B2 (ja) 2019-09-25
KR20160003648A (ko) 2016-01-11
CA2903394C (en) 2021-08-31
US20240182426A1 (en) 2024-06-06
EA030481B1 (ru) 2018-08-31
WO2014153226A9 (en) 2015-01-08
SI2970132T1 (sl) 2021-02-26
US20160024016A1 (en) 2016-01-28
IL268189B (en) 2022-02-01
IL241368B (en) 2019-07-31
AU2014236146A1 (en) 2015-09-10
AU2018203056A1 (en) 2018-07-19
CN105339351B (zh) 2018-11-06
CN109265400A (zh) 2019-01-25
CN109265400B (zh) 2022-10-04
IL241368A0 (en) 2015-11-30
SG11201506972PA (en) 2015-10-29
AU2018203056B2 (en) 2020-05-21
CY1123637T1 (el) 2022-03-24
US20210078951A1 (en) 2021-03-18
US20190100496A1 (en) 2019-04-04
ES2837034T3 (es) 2021-06-29
EP2970132A1 (en) 2016-01-20
KR20190112334A (ko) 2019-10-04
CN105339351A (zh) 2016-02-17
RS61231B1 (sr) 2021-01-29
PL2970132T3 (pl) 2021-04-06
ZA201507441B (en) 2021-01-27
CA2903394A1 (en) 2014-09-25
WO2014153226A1 (en) 2014-09-25
IL268189A (en) 2019-09-26
HRP20202008T1 (hr) 2021-02-19
DK2970132T3 (da) 2020-12-21
MX382991B (es) 2025-03-13
EP2970132B1 (en) 2020-09-23
AU2014236146B2 (en) 2018-05-17

Similar Documents

Publication Publication Date Title
IL268189B (en) Arginine methyltransferase inhibitors and their uses
IL267681A (en) Selective grp94 inhibitors and their uses
IL241370A0 (en) Carm1 inhibitors and their uses
IL240239A0 (en) erk inhibitors and their uses
GB2549372B8 (en) Electrosurgical methods and systems
EP2968339A4 (en) Mk2 inhibitors and uses thereof
ZA201505626B (en) Electrosurgical systems and methods
EP2994128A4 (en) ACC-HEMMER AND USES THEREOF
EP2994138A4 (en) ACC-HEMMER AND USES THEREOF
EP3200588A4 (en) Arginine methyltransferase inhibitors and uses thereof
EP2994139A4 (en) ACC-HEMMER AND USES THEREOF
HUE039504T2 (hu) Kináz inhibitor és alkalmazása
EP2943202A4 (en) IRAQ INHIBITORS AND USES THEREOF
ZA201508355B (en) Acc inhibitors and uses thereof
IL243728B (en) rorc2-inhibiting indole derivatives and their uses
IL244214A0 (en) Thienopiperidine derivative and its use
IL240553A0 (en) il-1ß inhibitory compounds and use thereof
GB201305813D0 (en) Compositions and methods
ZA201601880B (en) Hetero-transglycosylase and uses thereof
EP2968274A4 (en) MEROPENE DERIVATIVES AND USES THEREOF
GB201301393D0 (en) Kiddibidet and pottibidet
GB201306926D0 (en) Turbine and clip